Open tender · Germany · Cn Standard
Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Relugolix (ATC-Code: L02BX04).
The work
Conclusion of a non-exclusive discount contract for the active substance Relugolix (ATC-Code: L02BX04) under § 130a Abs. 8 SGB V.
- Contract must be for Relugolix (ATC-Code: L02BX04).
- Contract must be non-exclusive.
- Contract must be concluded within the period from 01.09.2025 to 31.08.2027.
Key facts
- Contract period
- Up to 24 months, ending no later than 31.08.2027.
- Evaluation
- Not a public procurement in the sense of Directive 2014/24/EU.
What it takes to qualify
Worth a closer look
- The tender is not a public procurement, so standard tender rules may not apply.
- The submission mode and envelope structure are not specified.
Experience
- At least 1 similar work — Experience as a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) under § 4 Abs. 18 AMG.
- Being a pharmaceutical entrepreneur with a seat in the AMG area, EU, or EEA.
Certifications and registrations
Pharmazeutischer Unternehmer statusMust be a pharmaceutical entrepreneur as defined by § 4 Abs. 18 AMG.
GST registration (optional)Not mentioned in the provided text.
Policy conditions
No reservation, preference or local-content restriction.
Documents to submit
- Contract documents and conditionsApplicants must request and submit the contractual documents.